Commercial NOtions

With lead compound naproxicinod completing its first Phase III trial in osteoarthritis ahead of schedule and having decided to develop NCX 4016 to treat Type II diabetes, NicOx S.A. is now focusing on making the transition from a research company to a fully integrated specialty pharmaceuticals business with franchises in rheumatology and cardiometabolism. The company laid out its new strategy for the first time last week.

"I haven't seen any company achieve success without selling its own drugs," Chairman

Read the full 785 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE